Jonathan M Snowden1, Yea-Hung Chen2, Willi McFarland3, Henry F Raymond4. 1. Portland, USA. 2. San Francisco, California, USA. 3. San Francisco Department of Public Health, San Francisco, California, USA. 4. HIV AIDS Statistics and Epidemiology, San Francisco Department of Public Health, San Francisco, California, USA.
Abstract
OBJECTIVES: Pre-exposure prophylaxis (PrEP) has gained a central role in prevention of HIV infection among men who have sex with men (MSM), particularly in San Francisco, California, USA. Programmes to enrol men in PrEP are being undertaken by a range of public and private organisations. PrEP will have the largest population impact if it reaches men who are most at risk for HIV infection, and is used in a manner that enables maximal efficacy. Access to PrEP also needs to be equitable. We report on the characteristics of men eligible for and using PrEP. METHODS: Data were from the 2014 implementation of National HIV Behavioural Surveillance (NHBS) among MSM in San Francisco. NHBS uses venue-based sampling as the national standard for sampling MSM. We compare proportions of demographic characteristics of MSM using versus not using PrEP who are HIV-negative and meet Centers for Disease Control and Prevention guidelines to recommend PrEP. RESULTS: Overall, 64.1% of HIV-negative MSM in San Francisco would meet guidelines for PrEP use, while 9.2% of MSM overall and 14.5% of MSM eligible were using PrEP as of 2014. Men using PrEP are more likely to be white and of older age. There were no differences between men using and not using PrEP in terms of education, income and health insurance. CONCLUSIONS: PrEP roll-out efforts should attempt to increase reach for young, black and Hispanic MSM. Failure to equitably provide access to PrEP could exacerbate the US disparity in new HIV infections for men of colour. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: Pre-exposure prophylaxis (PrEP) has gained a central role in prevention of HIV infection among men who have sex with men (MSM), particularly in San Francisco, California, USA. Programmes to enrol men in PrEP are being undertaken by a range of public and private organisations. PrEP will have the largest population impact if it reaches men who are most at risk for HIV infection, and is used in a manner that enables maximal efficacy. Access to PrEP also needs to be equitable. We report on the characteristics of men eligible for and using PrEP. METHODS: Data were from the 2014 implementation of National HIV Behavioural Surveillance (NHBS) among MSM in San Francisco. NHBS uses venue-based sampling as the national standard for sampling MSM. We compare proportions of demographic characteristics of MSM using versus not using PrEP who are HIV-negative and meet Centers for Disease Control and Prevention guidelines to recommend PrEP. RESULTS: Overall, 64.1% of HIV-negative MSM in San Francisco would meet guidelines for PrEP use, while 9.2% of MSM overall and 14.5% of MSM eligible were using PrEP as of 2014. Men using PrEP are more likely to be white and of older age. There were no differences between men using and not using PrEP in terms of education, income and health insurance. CONCLUSIONS: PrEP roll-out efforts should attempt to increase reach for young, black and Hispanic MSM. Failure to equitably provide access to PrEP could exacerbate the US disparity in new HIV infections for men of colour. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
ANTIRETROVIRAL THERAPY; EPIDEMIOLOGY (GENERAL); GAY MEN; HIV
Authors: Sybil G Hosek; George Siberry; Margo Bell; Michelle Lally; Bill Kapogiannis; Keith Green; M Isabel Fernandez; Brandy Rutledge; Jaime Martinez; Robert Garofalo; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Lauren B Beach; George J Greene; Peter Lindeman; Amy K Johnson; Christian N Adames; Matthew Thomann; Patrick C T Washington; Gregory Phillips Journal: AIDS Patient Care STDS Date: 2018-11 Impact factor: 5.078
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Jonathan M Snowden; Sarah S Osmundson; Menolly Kaufman; Cori Blauer Peterson; Katy Backes Kozhimannil Journal: Health Serv Res Date: 2020-07-16 Impact factor: 3.402
Authors: Angel B Algarin; Cho Hee Shrader; Chintan Bhatt; Benjamin T Hackworth; Robert L Cook; Gladys E Ibañez Journal: J Urban Health Date: 2019-12 Impact factor: 3.671
Authors: Christian Grov; Anthony W P Flynn; Alexa B D'Angelo; Javier Lopez-Rios; David W Pantalone; Ian W Holloway; Jeffrey T Parsons Journal: Prev Sci Date: 2019-01
Authors: David A Katz; Julia C Dombrowski; Michael Barry; Dawn Spellman; Teal R Bell; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Christian Grov; Alexa B D'Angelo; Anthony W P Flynn; Javier Lopez-Rios; David W Pantalone; Ian W Holloway; Thomas H F Whitfield; Jeffrey T Parsons Journal: AIDS Educ Prev Date: 2018-08
Authors: Ronald A Brooks; Vincent C Allen; Rotrease Regan; Matt G Mutchler; Ramon Cervantes-Tadeo; Sung-Jae Lee Journal: Int J STD AIDS Date: 2017-08-30 Impact factor: 1.359